Peginterferon alfa and ribavirin for chronic hepatitis c in patients eligible for shortened treatment, re-treatment or in HCV/HIV co-infection: A systematic review and economic evaluation

Health Technology Assessment

Volumn 15, Issue 17, 2011, Pages 1-208

  Hartwell, D ^a   Jones, J ^a   Baxter, L ^a   Shepherd, J ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; NUCLEOSIDE DERIVATIVE; PEGINTERFERON; PEGINTERFERON ALPHA; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2A PLUS RIBAVIRIN; PEGINTERFERON ALPHA2B; PEGINTERFERON ALPHA2B PLUS RIBAVIRIN; PROTEINASE INHIBITOR; RIBAVIRIN; RIBAVIRIN TEVA; UNCLASSIFIED DRUG; VIRUS RNA;

CLINICAL EFFECTIVENESS; COHORT ANALYSIS; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC TEST; DISEASE COURSE; DISEASE SEVERITY; DRUG COST; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESEARCH; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ECONOMIC EVALUATION; GENOTYPE; GEOGRAPHIC DISTRIBUTION; HEALTH CARE COST; HEPATITIS C; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; LIFE EXPECTANCY; LIVER CIRRHOSIS; LIVER TOXICITY; MIXED INFECTION; MONOTHERAPY; NATIONAL HEALTH SERVICE; NONHUMAN; PATIENT CARE; PATIENT MONITORING; PREVALENCE; PROGNOSIS; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; RELAPSE; RETREATMENT; REVIEW; SHORT COURSE THERAPY; STATISTICAL MODEL; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT RESPONSE; UNITED KINGDOM; UNSPECIFIED SIDE EFFECT; VIRUS LOAD;

ANTIVIRAL AGENTS; CONFIDENCE INTERVALS; COST-BENEFIT ANALYSIS; DRUG THERAPY, COMBINATION; GENOTYPE; GREAT BRITAIN; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; INTERFERON ALFA-2A; POLYETHYLENE GLYCOLS; PROBABILITY; QUALITY-ADJUSTED LIFE YEARS; RIBAVIRIN; RISK ASSESSMENT; STATE MEDICINE; TREATMENT OUTCOME; UNCERTAINTY;

EID: 79960752912     PISSN: 13665278     EISSN: None     Source Type: Journal    
DOI: 10.3310/hta15170     Document Type: Review

References (121)

1. Thomson BJ, Finch RG. Hepatitis C virus infection. Clin Microbiol Infect 2005;11:86-94.
2. Flamm SL. Chronic hepatitis C virus infection. JAMA 2003;289:2413-17.
3. Health Protection Agency (HPA). Hepatitis C in the UK: 2008 report. London: Health Protection Agency Centre for Infections; 2008.
4. Booth J, O'Grady J, Neuberger J, on behalf of the Royal College of Physicians of London and the British Society of Gastroenterology. Clinical guidelines on the management of hepatitis C. Gut 2001;49:1-21.
5. Hoofnagle JH. Hepatitis C: the clinical spectrum of disease. Hepatology 1997;26:S15-20.
6. Foster GR, Goldin RD, Thomas HC. Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis. Hepatology 1998;27:209-12.
7. Giraudon I, Ruf M, Maguire H, Charlett A, Ncube F, Turner J, et al. Increase in diagnosed newly acquired hepatitis C in HIV-positive men who have sex with men across London and Brighton, 2002-2006: is this an outbreak? Sex Transm Infect 2008;84:111-15.
8. Global Burden Of Hepatitis C Working Group. Global burden of disease (GBD) for hepatitis C. J Clin Pharmacol 2004;44:20-9.
9. Health Protection Agency Centre for Infections, Health Protection Scotland, National PublicHealth Service for Wales, Communicable Disease Surveillance Centre, Northern Ireland, Centre for Research on Drugs & Health Behaviour, London School of Hygiene & Tropical Medicine. Shooting up: infections among injecting drug users in the United Kingdom 2006. London: Health Protection Agency; 2007.
10. Mohsen A, Easterbrook P, Taylor C, Norris S. Hepatitis C and HIV-1 coinfection. Gut2002;51:601-8.
11. Pol S, Soriano V. Management of chronic hepatitis C virus infection in HIV-infected patients. Clin Infect Dis 2008;47:94-101.
12. Thomson EC, Main J. Epidemiology of hepatitis C virus infection in HIV-infected individuals. J Viral Hepat 2008;15:773-81.
13. Desmet VJ. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. J Hepatol 2003; 38:382-6.
14. Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981;1:431-5.
15. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995;22:696-9.
16. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996;24:289-93.
17. Shepherd J, Jones J, Hartwell D, Davidson P, Price A, Waugh N. Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of mild chronic hepatitis C: a systematic review and economic evaluation. Health Technol Assess 2007;11(11).
18. Sweeting MJ, De Angelis D, Neal KR, Ramsay ME, Irving WL, Wright M, et al. Estimated progression rates in three United Kingdom hepatitis C cohorts differed according to method of recruitment. J Clin Epidemiol 2006;59:144-52.
19. Alberti A, Vario A, Ferrari A, Pistis R. Review article: chronic hepatitis C-natural history and co-factors. Aliment Pharmacol Ther 2005;22:74-8.
20. Sweeting MJ, De Angelis D, Brant LJ, Harris HE, Mann AG, Ramsay ME. The burden of hepatitis C in England. J Viral Hepat 2007;14:570-6.
21. Di Bisceglie AM. Hepatitis C. Lancet 1998;351:351-5.
22. Poynard T, Ratziu V, Charlotte F, Goodman Z, McHutchison J, Albrecht J. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. J Hepatol 2001;34:730-9.
23. Martinez-Sierra C, Arizcorreta A, Diaz F, Roldan R, Martin-Herrera L, Perez-Guzman E, et al. Progression of chronic hepatitis C to liver fibrosis and cirrhosis in patients coinfected with hepatitis C virus and human immunodeficiency virus. Clin Infect Dis 2003;36:491-8.
24. Martin-Carbonero L, Benhamou Y, Puoti M, Berenguer J, Mallolas J, Quereda C, et al. Incidence and predictors of severe liver fibrosis in human immunodeficiency virusinfected patients with chronic hepatitis C: a European collaborative study. Clin Infect Dis 2004;38:128-33.
25. Graham CS, Baden LR, Yu E, Mrus JM, Carnie J, Heeren T, et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a metaanalysis. Clin Infect Dis 2001;33:562-9.
26. Mohsen AH, Easterbrook PJ, Taylor C, Portmann B, Kulasegaram R, Murad S, et al. Impact of human immunodeficiency virus (HIV) infection on the progression of liver fibrosis in hepatitis C virus infected patients. Gut 2003;52:1035-40.
27. Poynard T, Mathurin P, Lai CL, Guyader D, Poupon R, Tainturier MH, et al. A comparison of fibrosis progression in chronic liver diseases. J Hepatol 2003;38:257-65.
28. Thein HH, Yi Q, Dore GJ, Krahn MD. Natural history of hepatitis C virus infection in HIVinfected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis. AIDS 2008;22:1979-91.
29. The Antiretroviral Therapy Cohort Collaboration. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet 2008;372:293-9.
30. Macias J, Melguizo I, Fernandez-Rivera FJ, Garcia-Garcia A, Mira JA, Ramos AJ, et al. Mortality due to liver failure and impact on survival of hepatitis virus infections in HIVinfected patients receiving potent antiretroviral therapy. Eur J Clin Microbiol Infect Dis 2002;21:775-81.
31. Mocroft A, Soriano V, Rockstroh J, Reiss P, Kirk O, De WS, et al. Is there evidence for an increase in the death rate from liver-related disease in patients with HIV? AIDS 2005;19:2117-25.
32. Scottish Intercollegiate Guidelines Network (SIGN). Management of hepatitis C. National Clinical Guideline 92. Edinburgh: SIGN; 2006.
33. National Institute for Health and Clinical Excellence (NICE). Peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis C. Technology Appraisal Guidance No. 106. London: NICE; 2006.
34. Veldt BJ, Saracco G, Boyer N, Camma C, Bellobuono A, Hopf U, et al. Long term clinical outcome of chronic hepatitis C patients with sustained virological response to interferon monotherapy. Gut 2004;53:1504-8.
35. Chander G, Sulkowski MS, Jenckes MW, Torbenson MS, Herlong HF, Bass EB, et al. Treatment of chronic hepatitis C: a systematic review. Hepatology 2002;36:S135-44.
36. Yoshida H, Arakawa Y, Sata M, Nishiguchi S, Yano M, Fujiyama S, et al. Interferon therapy prolonged life expectancy among chronic hepatitis C patients. Gastroenterol 2002;123:483-91.
37. Gluud C, Brok J, Gong Y, Koretz RL. Hepatology may have problems with putative surrogate outcome measures. J Hepatol 2007;46:734-42.
38. National Institute for Clinical Excellence (NICE). Interferon alfa (pegylated and nonpegylated) and ribavirin for the treatment of chronic hepatitis C. Technology Appraisal Guidance No. 75. London: NICE; 2004.
39. Davis GL. Monitoring of viral levels during therapy of hepatitis C. Hepatology 2002;36:S145-51.
40. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-65.
41. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-82.
42. Roche UK. Summary of Product Characteristics-Peginterferon alfa-2a (Pegasys). Electronic Medicines Compendium 2009. URL: http://emc.medicines.org.uk/medicine/10081/SPC/Pegas ys135mcgand180mcgsolutionforinjectioninPre-filledSyringe/(accessed 18 May 2009).
43. Schering-Plough. Summary of Product Characteristics-Peginterferon alfa-2b (ViraferonPeg). Electronic Medicines Compendium 2009. URL: http://emc.medicines.org.uk/medicine/10321/SPC/ViraferonPegPen50%2c80%2c100%2c120or150microgramspowderand solventforsolutionforinjectioninpre-filledpen/(accessed 18 May 2009).
44. Shepherd J, Brodin H, Cave C, Waugh N, Price A, Gabbay J. Pegylated interferon α-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation. Health Technol Assess 2004;8(39).
45. Rockstroh JK, Bhagani S, Benhamou Y, Bruno R, Mauss S, Peters L, et al. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults. HIV Med 2008;9:82-8.
46. Nelson M, Matthews G, Brook MG, Main J, Bateman P, Gilson R, et al. BHIVA guidelines on HIV and chronic hepatitis: coinfection with HIV and hepatitis C virus infection (2005). HIV Med 2005;6:96-106.
47. British Medical Association and Royal Pharmaceutical Society of Great Britain. British national formulary. No. 58, September 2009. London: BMA and RPS; 2009.
48. Hartwell D, Shepherd J. Pegylated and non-pegylated interferon-alfa and ribavirin for the treatment of mild chronic hepatitis C: a systematic review and meta-analysis. Int J Technol Assess Health Care 2009;25:56-62.
49. Centre for Reviews and Dissemination (CRD). Systematic reviews: CRD's guidance for undertaking reviews in health care. 3rd edn. York Publishing Services: CRD; 2009.
50. Zhao S, Cheng D, Liu E, Yu H, Yang H, Xue X, et al. Peginterferon vs. interferon in thetreatment of different HCV genotype infections in HIV patients. Eur J Clin Microbiol Infect Dis 2008;27:1183-92.
51. Kim AI, Dorn A, Bouajram R, Saab S. The treatment of chronic hepatitis C in HIV-infected patients: a meta-analysis. HIV Med 2007;8:312-21.
52. Mangia A, Minerva N, Bacca D, Cozzolongo R, Ricci GL, Carretta V, et al. Individualized treatment duration for hepatitis C genotype 1 patients: a randomized controlled trial. Hepatology 2008;47:43-50.
53. Liu C-H, Liu C-J, Lin C, Liang C-C, Hsu S-J, Yang S-S, et al. Pegylated interferon-alpha-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trial. Clin Infect Dis 2008;47:1260-9.
54. Yu ML, Dai CY, Huang JF, Chiu CF, Yang YH, Hou NJ, et al. Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial. Hepatology 2008;47:1884-93.
55. Yu ML, Dai CY, Huang JF, Hou NJ, Lee LP, Hsieh MY, et al. A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C. Gut 2007;56:553-9.
56. von Wagner M, Huber M, Berg T, Hinrichsen H, Rasenack J, Heintges T, et al. Peginterferonalpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology 2005;129:522-7.
57. Liu CH, Liu CJ, Lin CL, Liang CC, Hsu SJ, Yang SS, et al. A randomized trial of 24- versus 48-week peginterferon alfa-2A plus ribavirin for treatment-naive Taiwanese patients with hepatitis C virus genotype 1 infection. Hepatology 2008;48:320A.
58. ®): prospective, randomized, controlled study comparing 24 and 48 weeks of treatment. Hepatology 2007;46:822-3A.
59. Berg T, Weich V, Teuber G, Klinker H, Moller B, Rasenack J, et al. Individualized treatment strategy according to early viral kinetics in hepatitis C virus type 1-infected patients. Hepatology 2009;50:369-77.
60. Younossi ZM, Nader FH, Bai C, Sjogren R, Ong JP, Collantes R, et al. A phase II dose finding study of darbepoetin alpha and filgrastim for the management of anaemia and neutropenia in chronic hepatitis C treatment. J Viral Hepat 2008;15:370-8.
61. National Institute for Health and Clinical Excellence (NICE). Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C (part-review of TA75 and TA106): final scope. URL: www.nice.org.uk/guidance/index.jsp?action=download&o=44230 (accessed May 2009).
62. Roche UK. Summary of Product Characteristics-Ribavirin (Copegus). Electronic Medicines Compendium 2009. URL: http://emc.medicines.org.uk/medicine/11755/SPC/Copegus200mg/(accessed 18 May 2009).
63. Nguyen-Khac E, Capron D, Castelain S, Francois C, Braillon A. Personalized therapy for chronic viral hepatitis C in the naive patient: how can we optimize treatment duration as a function of viral genotype? Eur J Inter Med 2007;18:510-15.
64. Kuehne FC, Bethe U, Freedberg K, Goldie SJ. Treatment for hepatitis C virus in human immunodeficiency virus-infected patients: clinical benefits and cost-effectiveness. Arch Intern Med 2002;162:2545-56.
65. Campos NG, Salomon JA, Servoss JC, Nunes DP, Samet JH, Freedberg KA, et al. Costeffectiveness of treatment for hepatitis C in an urban cohort co-infected with HIV. Am J Med 2007;120:272-9.
66. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, Lissen E, Gonzalez-Garcia J, Lazzarin A, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004;351:438-50.
67. Drummond MF, Sculpher MJ, O'Brien BJ, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press; 2005.
68. National Institute for Health and Clinical Excellence (NICE). Guide to the methods of technology appraisal. 2008. URL: www.nice.org.uk/media/B52/A7/TAMethodsGuideUpdatedJune2008.pdf (accessed August 2009).
69. Philips Z, Ginnelly L, Sculpher M, Claxton K, Golder S, Riemsma R, et al. Review ofguidelines for good practice in decision-analytic modelling in health technology assessment. Health Technol Assess 2004;8(36).
70. Soto B, Sanchez-Quijano A, Rodrigo L. Human immunodeficiency virus infection modifies the natural history of chronic parenterally acquired hepatitis C with an unusually rapid progression to cirrhosis. J Hepatol 1997;26:1-5.
71. Di Martino V, Rufat P, Boyer N. The influence of human immunodeficiency virus coinfection on chronic hepatitis C in injection drug users: a long-term retrospective cohort study. Hepatology 2001;34:1193-9.
72. Schackman BR, Goldie SJ, Freedberg KA, Losina E, Brazier J, Weinstein MC. Comparison of health state utilities using community and patient preference weights derived from a survey of patients with HIV/AIDS. Med Decis Making 2002;22:27-38.
73. Bozzette, S, Berry, SH, Duan N, Frankel MR, Leibowitz AA, Lefkowitz D, et al., for the HIV Cost and Services Utilization Study Consortium. The care of HIV-infected adults in the United States. N Engl J Med 1998;339:1897-904.
74. Multiattribute utility function for a comprehensive health status classification system: Health Utilities Index Mark 2. Med Care 1996;34:702-22.
75. Brazier J, Usherwood T, Harper R and Thomas K. Deriving a preference-based single index from the UK SF-36 Health Survey. J Clin Epidemiol 1998;51:1115-28.
76. Bennett WG, Inoue Y, Beck JR, Wong JB, Pauker SG, Davis GL. Estimates of the costeffectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C. Ann Intern Med 1997;127:855-65.
77. Davis GL, Beck JR, Farrell G, Poynard T. Prolonged treatment with interferon in patients with histologically mild chronic hepatitis C: a decision analysis. J Viral Hepat 1998;5:313-21.
78. Wong JB, Koff RS. Watchful waiting with periodic liver biopsy versus immediate empirical therapy for histologically mild chronic hepatitis C: a cost-effectiveness analysis. Ann Intern Med 2000;133:665-75.
79. Salomon JA, Weinstein MC, Hammitt JK, Goldie SJ. Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population. JAMA 2003;290:228-37.
80. Grieve R, Roberts J. Economic evaluation for hepatitis C. Acta Gastroenterol Belg 2002;65:104-9.
81. Grieve R, Roberts J, Wright M, Sweeting M, Deagelis D, Rosenberg W, et al. Costeffectiveness of interferon alpha or peginterferon alpha with ribavirin for histologically mild chronic hepatitis C. Gut 2006;55:1332-8.
82. Wright M, Grieve R, Roberts J, Main J, Thomas HC, UK Mild Hepatitis C Trial Investigators. Health benefits of antiviral therapy for mild chronic hepatitis C: randomised controlled trial and economic evaluation. Health Technol Assess 2006;10(21).
83. Kind P, Hardman G, Macran S. UK Population norms for EQ-5D. Centre for Health Economics Discussion Paper 172. York: Centre for Health Economics, University of York; 1999.
84. Dolan P, Gudex C, Kind P, Williams A. A social tariff for EuroQol: results from a UK general population survey. Centre for Health Economics Discussion Paper 138. York: Centre for Health Economics, University of York; 1995.
85. Curtis L. Unit costs of health and social care. Canterbury: Personal Social Services Research Unit, University of Kent; 2008.
86. Stinnett AA, Mullahy J. Net health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analysis. Med Dec Making 2009;18:S68-80.
87. Bruno S, Stroffolini T, Colombo M, Bollani S, Benvegnu L, Mazzella G, et al. Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology 2007;45:579-87.
88. Jensen DM, Marcellin P, Freilich B, Andreone P, Di BA, Brandao-Mello CE, et al. Re-treatment of patients with chronic hepatitis C who do not respond to peginterferonalpha2b: a randomized trial. Ann Intern Med 2009;150:528-40.
89. Berg C, Goncales FL Jr, Bernstein DE, Sette H Jr, Rasenack J, Diago M, et al. Re-treatment of chronic hepatitis C patients after relapse: efficacy of peginterferon-alpha-2a (40 kDa) and ribavirin. J Viral Hepat 2006;13:435-40.
90. Shiffman ML, Suter F, Bacon BR, Nelson D, Harley H, Sola R, et al. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med 2007;357:124-34.
91. Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferonalpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;140:346-55.
92. Schering-Plough Ltd. Pegylated interferon alfa-2b and ribavirin for hepatitis C: re-treatment of patients previously failing therapy and treatment of HIV/HCV co-infected patients. NICE MTA submission, 2009.
93. Ratcliffe J, Longworth L, Young T, Bryan S, Burroughs A, Buxton M, et al. Assessing healthrelated quality of life pre- and post-liver transplantation: a prospective multicenter study. Liver Transpl 2002;8:263-70.
94. Laguno M, Cifuentes C, Murillas J, Veloso S, Larrousse M, Payeras A, et al. Randomized trial comparing pegylated interferon alpha-2b versus pegylated interferon alpha-2a, both plus ribavirin, to treat chronic hepatitis C in human immunodeficiency virus patients. Hepatology 2009;49:22-31.
95. Laguno M, Murillas J, Blanco JL, Martinez E, Miquel R, Sanchez-Tapias JM, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients. AIDS 2004;18:F27-36.
96. Poynard T, Schiff E, Terg R, Moreno Otero R, Flamm S, Schmidt W, et al. Sustained viral response (SVR) is dependent on baseline characteristics in the re-treatment of previous alfa interferon/ribavirin (I/R) nonresponders (NR): final results from the EPIC3 program. 43rd Annual Meeting of the European Association for the Study of the Liver (EASL), Milan, Italy, 23-27 April 2008.
97. Scotto G, Fazio V, Fornabaio C, Tartaglia A, Di TR, Saracino A, et al. Peg-interferon alpha-2a versus Peg-interferon alpha-2b in nonresponders with HCV active chronic hepatitis: a pilot study. J Interferon Cytokine Res 2008;28:623-9.
98. Fattovich G, Giustina G, Degos F, Tremolada F, Diodati G, Almasio P, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterol 1997;112:463-72.
99. Sonnenberg FA, Gregory P, Yomtovian R, Russell LB, Tierney W, Kosmin M, et al. The costeffectiveness of autologous transfusion revisited: implications of an increased risk of bacterial infection with allogeneic transfusion. Transfusion 1999;39:808-7.
100. Boring CC, Squires TS, Tong T. Cancer statistics, 1993. CA Cancer J Clin 1993;43:7-26.
101. Mohsen AH, Trent HCV Study Group. The epidemiology of hepatitis C in a UK health regional population of 5.12 million. Gut 2001;48:707-13.
102. Foster GR, Goldin RD, Main J, Murray-Lyon I, Hargreaves S, Thomas HC. Management of chronic hepatitis C: clinical audit of biopsy based management algorithm. BMJ 1997;315:453-8.
103. Siebert U, Sroczynski G, Rossol S, Wasem J, Ravens-Sieberer U, Kurth BM, et al. Costeffectiveness of peginterferon alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C. Gut 2003;52:425-32.
104. Roche. Pegasys (peginterferon alfa-2a) and ribavirin for the treatment of chronic hepatitis C (part-review of TA75 and TA106). NICE MTA submission, 2009.
105. Longworth L, Young T, Ratcliffe J, Bryan S, Buxton M. Economic evaluation of the transplantation programme in England and Wales: an assessment of the costs of liver transplantation. Unpublished report to the Department of Health, 2001.
106. NHS Centre for Reviews and Dissemination (CRD). NHS economic evaluation database handbook. URL: www.york.ac.uk/inst/crd/pdf/nhseed-handb07.pdf Apr./2007. (accessed 20 August 2008).
107. Shiffman ML, Di Bisceglie AM, Lindsay KL, Morishima C, Wright EC, Everson GT, et al. Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology 2004;126:1015-23.
108. Everson GT, Hoefs JC, Seeff LB, Bonkovsky HL, Naishadham D, Shiffman ML, et al. Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C trial. Hepatology 2006;44:1675-84.
109. Shiffman ML, Mihas AA, Millwala F, Sterling RK, Luketic VA, Stravitz RT, et al. Treatment of chronic hepatitis C virus in African Americans with genotypes 2 and 3. Am J Gastroenterol 2007;102:761-6.
110. Yoshida EM, Sherman M, Bain VG, Cooper CL, Deschenes M, Marotta PJ, et al. Retreatment with pegylated interferon alpha-2a and ribavirin in patients with chronic hepatitis C who have relapsed or not responded to a first course of pegylated interferon-based therapy. Can J Gastroenterol 2009;23:180-4.
111. Parise ER, de Oliveira AC, Conceicao RDO, Amaral AC, Leite K. Response to treatment with interferon-alpha and ribavirin in patients with chronic hepatitis C virus genotypes 2 and 3 depends on the degree of hepatic fibrosis. Braz J Infect Dis 2006;10:78-81.
112. Zeuzem S, Pawlotsky JM, Lukasiewicz E, von WM, Goulis I, Lurie Y, et al. International, multicenter, randomized, controlled study comparing dynamically individualized versus standard treatment in patients with chronic hepatitis C. J Hepatol 2005;43:250-7.
113. Jensen DM, Morgan TR, Marcellin P, Pockros PJ, Reddy KR, Hadziyannis SJ, et al. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology 2006;43:954-60.
114. Ferenci P, Fried MW, Shiffman ML, Smith CI, Marinos G, Goncales FL Jr, et al. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J Hepatol 2005;43:425-33.
115. Ferenci P, Laferl H, Scherzer TM, Gschwantler M, Maieron A, Brunner H, et al. Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response. Gastroenterology 2008;135:451-8.
116. Carrat F, Bani-Sadr F, Pol S, Rosenthal E, Lunel-Fabiani F, Benzekri A, et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA 2004;292:2839-48.
117. Pol S, Carrat F, Bani-Sadr F, Rosenthal E, Lunel F, Morand P, et al. Final results of ANRS HC02-ribavic: A randomized controlled trial of pegylated-interferon alpha-2b plus ribavirin vs interferon alpha-2b plus ribavirin for naive HCV-HIV co- infected patients. J Hepatol 2005;42:10-11.
118. Chung RT, Andersen J, Volberding P, Robbins GK, Liu T, Sherman KE, et al. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIVcoinfected persons. N Engl J Med 2004;351:451-9.
119. Crespo M, Sauleda S, Esteban JI, Juarez A, Ribera E, Andreu AL, et al. Peginterferon alpha-2b plus ribavirin vs interferon alpha-2b plus ribavirin for chronic hepatitis C in HIV-coinfected patients. J Viral Hepat 2007;14:228-38.
120. Cargnel A, Angeli E, Mainini A, Gubertini G, Giorgi R, Schiavini M, et al. Open, randomized, multicentre Italian trial on PEG-IFN plus ribavirin versus PEG-IFN monotherapy for chronic hepatitis C in HIV-coinfected patients on HAART. Antivir Ther 2005;10:309-17.
121. Briggs A, Claxton K, Sculpher M. Decision modelling for health economic evaluation. Handbooks in Health Economic Evaluation. Oxford: Oxford University Press; 2006.